Arcutis Announces Additions to its Investor Relations and Communications Team
August 02 2021 - 3:05PM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing meaningful
innovations to address the urgent needs of patients living with
immune-mediated dermatological diseases and conditions, or
immuno-dermatology, today announced leadership additions to
investor relations and communications functions.
“We are delighted to have Eric McIntyre joining us to lead our
investor relations, and Amanda Shelton to head our communications
function. Their appointments will be critical as we enter our next
phase of growth, including our anticipated first New Drug
Application and potential commercial launch, as well as the
continued communication of our robust product pipeline,” said Frank
Watanabe, Arcutis’ President and Chief Executive Officer. “Their
breadth of biopharmaceutical experience complements our experienced
leadership team, which continues to be a key differentiator and
driver of our strong execution.”
Eric McIntyre brings nearly 15 years of biopharmaceutical,
finance, and investor relations experience. He will be responsible
for directing all investor relations activities, including
communicating business objectives and accomplishments to the
broader investment community. Previously, Mr. McIntyre spent 10
years at Amgen in roles of increasing responsibility across
investor relations, financial planning & analysis, and
valuation, including experience in the inflammation and dermatology
business.
Amanda Sheldon brings over 20 years of healthcare communications
experience including an extensive track record building advocacy
and brand loyalty for Fortune 100 and start-up pharmaceutical and
medical device companies. She will be responsible for leading the
overall strategic direction and implementation of internal and
external communications across the organization, including
corporate positioning, branding and identity, product
communications, social media strategy, and social responsibility.
Previously, she was vice president of marketing and communications
for the FH Foundation, responsible for improving awareness and
diagnosis of genetic lipid disorders. In addition, Amanda held
multiple communications and digital marketing roles at Medtronic,
where she established a first-of-its-kind patient social community
that increased brand awareness for diabetes therapies.
About ArcutisArcutis Biotherapeutics, Inc.
(Nasdaq: ARQT) is a medical dermatology company that champions
meaningful innovation to address the urgent needs of patients
living with immune-mediated dermatological diseases and conditions.
With a commitment to solving the most persistent patient challenges
in dermatology, Arcutis harnesses our unique dermatology
development platform coupled with our dermatology expertise to
build differentiated therapies against biologically validated
targets. Arcutis’ dermatology development platform includes a
robust pipeline with seven clinical programs for a range of
inflammatory dermatological conditions, with our first NDA
submission anticipated late in the third quarter or early in the
fourth quarter of 2021, and three more Phase 3 clinical data
readouts anticipated over the next 18 months. The company’s lead
product candidate, topical roflumilast, has the potential to
advance the standard of care for plaque psoriasis, atopic
dermatitis, scalp psoriasis, and seborrheic dermatitis. For more
information, visit www.arcutis.com or follow Arcutis
on LinkedIn and Twitter.
Forward-Looking StatementsThis press release
contains "forward-looking" statements, including, among others,
statements regarding the potential for filing Arcutis’s first New
Drug Application and commercial launch of roflumilast to
revolutionize the standard of care in plaque psoriasis and other
inflammatory dermatological conditions. These statements involve
substantial known and unknown risks, uncertainties, and other
factors that may cause our actual results, levels of activity,
performance, or achievements to be materially different from the
information expressed or implied by these forward-looking
statements and you should not place undue reliance on our
forward-looking statements. Risks and uncertainties that may cause
our actual results to differ include risks inherent in the clinical
development process and regulatory approval process, the timing of
regulatory filings, and our ability to defend our intellectual
property. For a further description of the risks and uncertainties
applicable to our business, see the "Risk Factors" section of our
Form 10-K filed with U.S. Securities and Exchange Commission (SEC)
on February 16, 2021, as well as any subsequent filings with the
SEC. We undertake no obligation to revise or update information
herein to reflect events or circumstances in the future, even if
new information becomes available.
Contacts:MediaAmanda Sheldon,
Head of Corporate Communicationsasheldon@arcutis.com
InvestorsEric McIntyre, Head of Investor
Relationsemcintyre@arcutis.com
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2024 to May 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From May 2023 to May 2024